34 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
Awards at 2023 Fiscal Year-End
DIRECTOR COMPENSATION
Director Compensation Table
CORPORATE GOVERNANCE
Board Structure
Independence of the Board … Management and Oversight
Shareholder Dialogue with the Company
Code of Business Conduct and Ethics
Corporate Governance Documents
Compensation
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of noncompliance.
We are subject to rules … to, and do not, comply with all best practice provisions of the Dutch Corporate Governance Code.
We are subject to the Dutch Corporate Governance Code
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
at 2023 Fiscal Year-End
DIRECTOR COMPENSATION
Director Compensation Table
CORPORATE GOVERNANCE
Board Structure
Independence of the Board of Directors … Management and Oversight
Shareholder Dialogue with the Company
Code of Business Conduct and Ethics
Corporate Governance Documents
Compensation Committee
POS AM
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
. No resolutions shall be adopted on items other than those that have been included in the agenda.
In accordance with the Dutch Corporate Governance Code … , with the assistance of our nomination and corporate governance committee. The Board of Directors will make any nomination for the appointment of a director with due
424B3
NAMS
NewAmsterdam Pharma Company NV
12 Mar 24
Prospectus supplement
4:18pm
with the Dutch Corporate Governance Code (the “DCGC”), shareholders who have the right to put an item on the agenda for the General Meeting or to request … of the Board of Directors, with the assistance of our nomination and corporate governance committee. The Board of Directors will make any nomination
POS AM
86r7neahf
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
10-K
bb57ct9p 7t
28 Feb 24
Annual report
8:00am
10-K
EX-4.4
7z24aijp8epzdn3et7c
28 Feb 24
Annual report
8:00am
424B5
99cbp
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
ir6du 0iyqgh
13 Feb 24
Prospectus supplement for primary offering
5:19pm
F-3
EX-1.2
pavx4d1m
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
ebzeplp3fg2w cc0yi
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
nf4pn
15 Aug 23
Prospectus supplement
4:52pm
POS AM
v16ve173
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
sb6q4qdyemhptcfjvivz
7 Aug 23
Research and development expenses
7:24am
424B3
suu0k
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-99.1
8i7cen
9 Jun 23
Current report (foreign)
9:39pm
424B3
2b8d3yss
8 Jun 23
Prospectus supplement
5:01pm
424B3
vuh1y05
6 Jun 23
Prospectus supplement
4:20pm
6-K
EX-99.1
fw800tfpbovp qm2
31 May 23
Current report (foreign)
8:00am